The dual impact of HIV-1 infection and aging on naïve CD4<sup>+</sup> T-cells: Additive and distinct patterns of impairment by Rickabaugh, TM et al.
The Dual Impact of HIV-1 Infection and Aging on Naı¨ve
CD4+ T-Cells: Additive and Distinct Patterns of
Impairment
Tammy M. Rickabaugh1, Ryan D. Kilpatrick1,7, Lance E. Hultin1, Patricia M. Hultin7, Mary Ann Hausner1,
Catherine A. Sugar3, Keri N. Althoff4, Joseph B. Margolick5, Charles R. Rinaldo6, Roger Detels7, John
Phair8, Rita B. Effros1,2, Beth D. Jamieson1*
1Department of Medicine, UCLA AIDS Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America,
2Department of Pathology and Laboratory Medicine, UCLA AIDS Institute, University of California Los Angeles, Los Angeles, California, United States of America,
3Department of Biostatistics, School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America, 4Department of
Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 5Department of Molecular Microbiology and
Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 6Graduate School of Public Health, University of
Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 7Department of Epidemiology, School of Public Health, University of California Los Angeles, Los Angeles,
California, United States of America, 8 Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America
Abstract
HIV-1-infected adults over the age of 50 years progress to AIDS more rapidly than adults in their twenties or thirties. In
addition, HIV-1-infected individuals receiving antiretroviral therapy (ART) present with clinical diseases, such as various
cancers and liver disease, more commonly seen in older uninfected adults. These observations suggest that HIV-1 infection
in older persons can have detrimental immunological effects that are not completely reversed by ART. As naı¨ve T-cells are
critically important in responses to neoantigens, we first analyzed two subsets (CD45RA+CD31+ and CD45RA+CD31-) within
the naı¨ve CD4+ T-cell compartment in young (20–32 years old) and older (39–58 years old), ART-naı¨ve, HIV-1 seropositive
individuals within 1–3 years of infection and in age-matched seronegative controls. HIV-1 infection in the young cohort was
associated with lower absolute numbers of, and shorter telomere lengths within, both CD45RA+CD31+CD4+ and
CD45RA+CD31-CD4+ T-cell subsets in comparison to age-matched seronegative controls, changes that resembled
seronegative individuals who were decades older. Longitudinal analysis provided evidence of thymic emigration and
reconstitution of CD45RA+CD31+CD4+ T-cells two years post-ART, but minimal reconstitution of the CD45RA+CD31-CD4+
subset, which could impair de novo immune responses. For both ART-naı¨ve and ART-treated HIV-1-infected adults, a
renewable pool of thymic emigrants is necessary to maintain CD4+ T-cell homeostasis. Overall, these results offer a partial
explanation both for the faster disease progression of older adults and the observation that viral responders to ART present
with clinical diseases associated with older adults.
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Introduction
The lifespan of an HIV-1-infected North American or
European individual is shortened by an average of 10 years,
despite antiretroviral therapy (ART) [1]. Many of the causes of
morbidity and mortality in these individuals are similar to those
more commonly observed in uninfected older adults (50–65 years
of age) and the elderly (.65 years of age), and include frailty [2],
non-Hodgkin’s lymphoma [3], anal and cervical carcinomas [4,5],
osteoporosis [6,7], liver [8–10] and renal impairment [11],
cardiovascular disease [12,13], diabetes [14] and hypertension
[14,15]. The diminished lifespan and higher prevalence of these
diseases in HIV-1-infected individuals, in comparison to age-
matched uninfected controls, has led to the theory that HIV-1
infection causes accelerated aging in multiple organ systems. As it
is not clear whether HIV-1 contributes to age-inappropriate
clinical manifestations through mechanisms distinct from aging, a
better understanding of the effects of HIV-1 infection and aging on
various organ systems is essential to future treatment of HIV-1-
infected individuals.
Survival time for HIV-1-infected adults both pre-and post-ART
is closely correlated with CD4+ T-cell counts. The life-expectancy
of an untreated HIV-1-infected individual with 200 CD4+ T-cells/
mm3 is approximately one to two years [16]. An ART-treated, 20-
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year-old adult with a CD4+ T-cell count under 200 cells/mm3 at
ART initiation is predicted to survive 32 years, compared to 50
years for an age-matched individual who initiates ART at a higher
CD4+ T-cell count [16]. An increased risk for frailty is also
associated with decreased CD4+ T-cell counts pre- and post-ART
initiation, as is the risk for non-Hodgkin lymphoma [2,3]. Poor
CD4+ T-cell recovery upon initiation of ART is also correlated
with an increased risk for both AIDS and non-AIDS diseases [17],
emphasizing the important role of the CD4+ T-cell compartment
in maintaining good health.
Although HIV-1 infection of naı¨ve CD4+ T-cells occurs at low
frequency in comparison to that of activated effector/memory
CD4+ T-cells, HIV-1 infection is associated with quantitative and
qualitative changes within the naı¨ve CD4+ T-cell compartment in
both children and adults [18–21]. In HIV-1-infected adults, a loss
of naı¨ve CD4+ T-cells precedes the loss of T-cell homeostasis and
progression to AIDS [20], and inverted naı¨ve to effector/memory
ratios are not always restored upon administration of ART
[17,22]. Since reconstitution of the naı¨ve T-cell compartment
contributes to reconstitution of overall CD4+ T-cell counts, a
continued deficit in naı¨ve CD4+ T-cell numbers would have
downstream implications for the effector/memory compartment.
In addition, functional defects, such as diminished antigen-specific
proliferative responses [23], persist in the naı¨ve CD4+ T-cell
compartment, despite treatment. As naı¨ve CD4+ T-cell prolifer-
ative responses post-ART predict immune responses to immuni-
zation with neoantigens [24], it is possible that an impaired naı¨ve
CD4+ T-cell compartment may contribute to the clinical
observations regarding poor health and age-associated pathologies
post-ART.
Aging, in the absence of HIV infection, is also associated with
quantitative and qualitative changes within the naı¨ve CD4+ T-cell
compartment [25–27]. Decreased numbers of recent thymic
emigrants (RTE), shortened telomeres, hyporesponsiveness to
stimulation, decreased proliferative capacity, reduced IL-2 pro-
duction, alterations in signal transduction and changes in cell
surface phenotype [26–28] have all been reported. These changes
likely contribute to the poor response to vaccines and increased
susceptibility to infectious diseases and neoplasms reported for
older adults [29–31] and possibly also contribute to the more rapid
disease progression in HIV-1-infected individuals over 50 years of
age.
Many factors, including co-infections and toxicity, or negative
side effects, of antiretroviral drugs, are likely to contribute to the
decreased lifespan and increased morbidities seen in HIV-1-
infected individuals. In the current study, we address the question
of whether HIV-1 infection accelerates the aging process by
characterizing the effects of HIV-1 infection and aging on the
naı¨ve CD4+ T-cell compartment. We investigate whether the
negative effects of HIV-1 infection and aging on the naı¨ve CD4+
T-cell compartment are additive or interactive. To this end, we
subdivided the naı¨ve CD4+ T-cell compartment into two
biologically disparate subsets based on the surface expression of
PECAM-1 (CD31), which distinguishes TREC high (CD31+)
naı¨ve CD4+ T-cells from their proliferative progeny, the TREC
low (CD31-) naı¨ve CD4+ T-cell subset [27,32]. We had previously
shown that aging is associated with changes in the relative
proportions of these two subsets and with telomere shortening
within cells from both subsets [27]. Therefore, in the current study
we compared the two naı¨ve CD4+ T-cell subsets within younger
(20–32 years old) and older (39–58 years old) HIV-1 seropositive
(SP) ART-naı¨ve adults relatively early in infection, as well as with
HIV-1 seronegative (SN) age-matched adults. Our results suggest
that the effects of HIV-1 infection and aging on the the naı¨ve
CD4+ T-cell compartment are both additive and distinct, and that
HIV-1 induced impairments are not fully restored to an age-
appropriate status by ART.
Materials and Methods
Ethics Statement
All study participants from the cross-sectional study were
recruited from the Los Angeles area. This study was approved
by the University of California, Los Angeles Medical Institutional
Review Board and each participant provided written, informed
consent per the approved protocol.
Participants
Cross-sectional study. Twenty-eight HIV-1 SN participants
aged 19–30 years, nineteen SN participants aged 47–60 years,
nine HIV-1 SP participants aged 20–32 years, and ten SP
participants aged 39–58 years. All SP participants were within 1–3
years of infection by self-report and were treatment-naı¨ve.
Longitudinal study. From the Multicenter AIDS Cohort Study
(MACS), a study of the natural and treated history of HIV-1
infection in men who have sex with men [33,34], we selected ten
SP men who initiated ART while enrolled in the MACS. ART is
self-reported during the semi-annual MACS study visits. Selection
criteria included the following characteristics at the visit prior to
initiating ART: an age of 40–50 years, an absolute T-cell count
.250 cells/mm3 of blood, a viral load .50 copies/ml (90% of
those selected had .5000 copies/ml), and a successful response to
treatment, defined by a viral load of ,400 RNA copies/ml
approximately one year post-ART (90% of those selected had a
viral load of ,50 RNA copies/ml). The average increase in
absolute CD4+ T-cell count one year post-ART was 147 cells/
mm3. Ten SN MACS participants, age-matched (within 6 months
to a year of age) to the pre-ART donor visit, were selected as
controls. We analyzed cryopreserved PBMC provided by these
men at 6 months to one year prior to ART initiation and at 1 and
2 years after that time.
Immunophenotyping and Cell Sorting
For the cross-sectional study, blood was collected into
ethylenediaminetetraacetic acid (EDTA)-treated vacutainer tubes
(Becton Dickinson, Rutherford, NJ). Whole blood was stained
with the following monoclonal antibodies: CD45RA fluorescein
isothiocyanate (FITC), CD4 peridinin chlorophyll protein
(PerCPTM), CD31 phycoerytherin (PE) and CD28 and/or CD27
allophycocyanin (APC), (BD Biosciences Immunocytometry Sys-
tems (BDIS), San Jose, CA). Whole blood was stained, lysed, and
analyzed as described [35]. PBMC for longitudinal analyses were
originally collected in heparin and cryopreserved in liquid
nitrogen. After thawing, the PBMC were stained as described
above and the cells were washed twice in 1 ml of 1X PBS
containing 2% newborn calf serum (NCS) and 0.1% sodium azide.
To aid in establishing a viable lymphocyte gate for cryopreserved
PBMC, an additional tube stained with 7-AAD, a marker for
cellular viability [36], was utilized. Samples were analyzed using a
FACSCaliburTM flow cytometer (BDIS) equipped with a 15 mW
air-cooled 488 nm argon-ion laser and a red diode laser emitting
at ,635 nm. For each sample, a minimum of 5,000 CD4+
lymphocytes were collected. Analysis of the data was performed
with CELLQuestTM software (BDIS).
Cell sorting was performed on a FACSAria flow cytometer
(BDIS). A singlet gate of side scatter height versus side scatter
width was used in addition to the standard forward scatter versus
side scatter gating, in order to exclude cell ‘‘doublets’’. PBMC,
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both freshly isolated as described [27], and cryopreserved, were
stained with CD45RA-FITC, CD31-PE, CD4-APC and CD8
APC-CY7 for cell sorting. The sorts for CD45RA+CD31+bright
CD4+ yielded cells that expressed 2-3 times more CD31 than
the sorts for CD45RA+CD31+dim CD4+. The sort gate for
CD45RA+CD31+dimCD4+ T-cells was very narrow in order to
exclude cells that were bright or negative for CD31. Based on
comparison with Quantibrite Phycoerythrin (PE) beads (BDIS),
CD45RA+CD31+brightCD4+ cells and CD45RA+CD31+dimCD4+
cells have a median staining intensity of 5700 and 1500 molecules of
PE, respectively [37,38]. The purities for sorted CD4+ T-cells were
all .99% and the subsets of CD4+ T-cells were .95% pure.
Measurement of Telomere length
Genomic DNA was extracted from PBMC using the DNeasy
Tissue Kit according to manufacturer’s instructions (Qiagen,
Valencia, California). Real-Time PCR was performed on a total of
5 ng of DNA per sample using IQ Sybr Green Supermix per
manufacturer’s instructions (Biorad, Hercules, California) and a
previously published quantitative telomere PCR protocol [39].
The primers used were: Tel 1b: 39-CGGTTTGTTTGGGTTT-
GGGTTTGGG TTTGGGTT TGGGTT-59 and Tel 2b: 39-G-
GCTTGCCTTACCCTTACCCTTACCCTT ACCCTTACC-
CT-59. The beta hemoglobin primers (used to quantify cell
numbers) were: HGB 1: 39-GCTTCTGACACAACTGTGTT-
CACTAGC-59 and HGB 2: 39-CACCAACTTCATCCACGTT-
CACC-59. Genomic DNA extracted from a B lymphoblastoid cell
line (BLCL) and from 1301 cells, a T-cell leukemia cell line with
extremely long telomere lengths (.25 kb) [40], were included in
each PCR reaction to control for inter-assay variation. A no-
template control was included in all PCR reactions, and data from
all samples were expressed as a percentage of the telomere length
of the 1301 cells, as described previously [27].
Measurement of TREC concentrations
TREC concentration was assessed by real-time PCR protocol as
described [41] and modified by us [42,43]. Briefly, cell lysates were
prepared by incubation of the cells with 100 mg of proteinase K
(Boehringer Ingelheim, Petersburg, Va.) per ml for at least 1 hour
at 56uC. Proteinase was inactivated by heating the sample for 10
minutes at 95uC. TREC were quantified by real-time PCR
analysis, using the 59 nuclease (TaqMan) assay and the ABI Prism
7700 sequence detector system (PE Biosystems) as described [43].
A 25-ml PCR mixture was used consisting of 5 ml of genomic DNA
solution, 2.5 ml of 10x PCR buffer, 1.75 ml of 50 mM MgCl2, 1 ml
of 5 mM deoxynucleoside triphosphates, 1 ml each of 12.5 pM
forward (39-CACATCC CTTTCAACCATGCT-59) and reverse
(39-GCCAGCTGCAGGGTTTAGG-59) primer and 1 ml of
5 mM probe (39-FAM-ACACCTCTGGTTTTTGTAAAGGTG-
CCCACT-Tamra/QSY-59) (MegaBases), 0.25 ml of 10 mM ROX
reference dye (Invitrogen), and 0.125 ml of platinum Taq
polymerase. The TREC standard consisted of known concentra-
tions (from 20/5ml – 26106/5ml) of a plasmid containing a
sjTREC fragment (kindly provided by D. Douek). Standard curves
and TREC concentrations in test samples were determined using
the software supplied with the ABI 7700. The number of cells in
each test sample was determined by using real-time PCR to
amplify b-actin DNA sequences (Applied Biosystems) per the
manufacturer’s instructions. All TREC and b-actin analyses were
performed in triplicate on the same plate. The average variability
of the triplicates was 9% for TREC measurements and 6% for the
b-actin measurements. The mean value for each triplicate was
used for statistical analyses.
Statistical Analysis
The cross-sectional analysis examined the joint effects of age
and HIV-1 serostatus on cell count and telomere length. Two-way
ANOVAs with main effects for age and serostatus and an
interaction term were followed, when significant, by post-hoc t-
tests for comparisons within each of the following compartments:
CD45RA+CD31+, CD45RA+CD31-, and CD45RA-mem (this
subset contains effector/memory cells). To assess relative differ-
ences between SP and SN subjects, we computed the ratios of the
average cell counts for these subgroups (SN to SP) within each age
range and compartment. To make comparisons across com-
partments, we also computed the differences in the ratios
for CD45RA+CD31+ vs. CD45RA+CD31-, CD45RA-mem vs.
CD45RA+CD31-, and CD45RA+31+ vs. CD45RA-mem in each
age range. Since the distribution of these ratios could not readily
be determined analytically, we employed a bootstrap resampling
procedure to obtain empirical p-values for the tests of cross-
compartment differences [44] as follows. First we generated
20,000 replicates of the original data set, sampling subjects with
replacement. For each of these ‘‘bootstrap’’ data sets we computed
the subgroup means, the ratios of SN to SP means within each age
range and compartment, and the corresponding differences in
ratios across compartments. We thus obtained an empirical
distribution for each of these quantities. Evidence of a significant
cross-compartmental difference in SN:SP ratio is based on
whether the corresponding empirical distribution lay almost
entirely above (or below) 0. A 95% confidence interval for the
difference was obtained by taking the 2.5% and 97.5% quantiles of
the empirical distribution. Similarly, we obtained two-sided p-
values for the ratio differences by doubling the tail probability
corresponding to where the empirical distribution crossed 0. We
took advantage of the same bootstrap simulations to validate the p-
values from ANOVA using the empirical distributions of the
differences in group means (analogous to t-tests). The bootstrap
analyses were performed in the R programming language.
To assess differences in TREC number between subjects with
high and low CD31 expression levels we used the non-parametric
two-sided Wilcoxon rank-sum tests due to the small sample sizes in
these subgroups. These analyses were performed using SAS,
version 9.1 (Cary, NC).
To assess changes in absolute cell counts post-ART, we fit a
linear mixed effects regression model. For absolute cell counts over
time, the model was the same as a standard linear regression,
except that a more sophisticated covariance structure was used to
account for the relationships among the repeated measures within
each subject. A significant positive coefficient of time would
suggest that cell counts increased post-ART, while a zero or
negative coefficient would suggest the opposite. Models were fit
using SAS PROC MIXED with a compound symmetric
covariance structure and time post-ART treated as a categorical
variable.
Results
Preferential loss of CD31- CD4+ naı¨ve T-cells during HIV-1
infection
We first quantified the percentage and absolute numbers of
CD31+CD45RA+CD27+CD3+CD4+ (CD31+CD4+ naı¨ve) and
CD31-CD45RA+CD27+ CD3+CD4+ (CD31-CD4+ naı¨ve) T-cells
in the peripheral blood of young (20-32 years of age) and older
(39–58 years of age) HIV-1-infected adults and age matched SN
controls. As shown in Figure 1A, both older age and HIV-1
infection were associated with significantly decreased numbers
of CD31+CD4+ T-cells. Young HIV-1-infected individuals
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demonstrated an average of 139 fewer CD31+CD4+ T-cells/mm3
than SN age-matched controls (317 cells/mm3 versus 178 cells/
mm3, respectively; p,0.0002), and in older SP individuals, HIV-1
was associated with an additional difference of 113 cells/mm3 in
this subset beyond what was accounted for by aging alone (223
cells/mm3 versus 110 cells/mm3, respectively; p = 0.0004). Since
there was no evidence of an interaction between age and HIV-1
infection (p = 0.6423), the effect of HIV-1 infection on
CD31+CD4+ T-cell numbers appears to be additive to the effects
of aging alone. Notably, the absolute number of CD31+ CD4+
naı¨ve T-cells in young SP individuals closely matched those of SN
participants who were 17 to 28 years their senior (Figure 1A).
HIV-1 infection, but not age, was associated with a significant
reduction of CD31-CD4+ naı¨ve T-cells. While younger SN
individuals had an average of 178 cells/mm3 CD31-CD4+ naı¨ve
T-cells, a decrease of 117 cells/mm3 was observed in the younger
SP individuals (p,0.0002). However, this effect was independent
of age; younger and older SP men had similar absolute cell
numbers (61 cells/mm3 and 75 cells/mm3, respectively; interac-
tion p = 0.9455). Aging in the absence of HIV-1 infection was not
significantly associated with a difference in the number of
CD31-CD4+ naı¨ve T-cells (an average of 178 cells/mm3 and
188 cells/mm3 in the younger and older groups respectively;
interaction p = 0.7476), consistent with previous reports by our
group [27] and others [45], demonstrating that HIV-1 infection is
associated with negative effects on this subset that are distinct from
aging.
Of note, the decrease in the absolute number of CD31-CD4+
naı¨ve T-cells associated with HIV-1 infection was greater than the
decrease observed for any other CD4+ T-cell phenotype tested
(Figure 1B). The number of CD31-CD4+ naı¨ve T-cells was 2.9
times lower in young SP participants than in young SN
participants (p = 0.0070). This is in contrast to a 1.8- and a 1.9-
fold difference in the numbers of CD31+CD4+ naı¨ve and
CD45RA- effector/memory T-cell subsets, respectively, between
the same two groups of participants (Figure 1B). There was also a
larger difference in CD31-CD4+ naı¨ve T-cell number between
older SN and older SP participants than in the CD31+CD4+
subset for these two groups, 2.5-fold versus 2.0-fold difference
respectively, but it did not reach significance. Whereas the loss of
either naı¨ve CD4+ T-cell subsets is likely to be detrimental to the
host, our previous study has shown that the CD45RA+CD31-
subset is particularly important for maintaining the naı¨ve CD4+ T-
cell pool during aging [27].
HIV-1 infection is associated with shortened telomeres
within naı¨ve CD4+ T-cells
As shown in Figure 2, HIV-1 infection was associated with
significant telomere shortening within both subsets of naı¨ve CD4+
T-cells across both age groups (younger: p = 0.0004 for CD31+,
p = 0.0096 for CD31-; older: p,0.0002 for both naive subsets). In
agreement with our previous findings [27], aging was also
associated with telomere shortening in both naı¨ve CD4+ T-cell
subsets, (younger vs. older SN: p = 0.0132 for CD31+ and
p = 0.0018 for CD31- subsets; younger vs. older SP: p = 0.0036
for CD31+ and p,0.0002 for CD31-). There was no evidence of
an interaction between age and HIV-1 infection in either naı¨ve
subset (interaction p = 0.9564 for CD31+ and p = 0.5492 for
CD31- CD4+ naı¨ve T-cell subsets) indicating that, although age
and HIV-1 serostatus each contribute to telomere shortening,
these effects appear to be additive.
CD31 expression correlates with TREC number in
CD31+CD4+ naive T-cells
Due to the challenge of obtaining the quantity of CD31+ CD4+
naı¨ve T-cells from both older adults and HIV-1-infected
Figure 1. ART-naı¨ve seropositive individuals 1-3 years post-
infection have significantly fewer naı¨ve CD4+ T-cells than
seronegative controls. PBMC from each individual in our cross-
sectional study were analyzed for the CD4+ naı¨ve T-cell subsets, defined
as CD45RA+CD27+ and either CD31+ or CD31-, and for the CD4+ T-cell
effector/memory subset, defined as CD45RA-CD27-, using flow cytom-
etry. A.) The distribution of the absolute number of naı¨ve and effector/
memory CD4+ T-cells was determined for each serotype and age group.
B.) The average absolute number of cells of each subset was
determined for each serotype and age group. For each subset, the
fold difference between the seronegative and seropositive age-
matched groups is shown above the bars. The asterisks signify the
following values, * p,0.05, ** p,0.01, ***p,0.005.
doi:10.1371/journal.pone.0016459.g001
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individuals required for TREC and telomere analysis, we
investigated alternative methods to determine the proliferative
history of CD31+CD4+ naı¨ve T-cells for use in the experiments
described below. Based on the observation that CD31 is
eventually lost from the surface of CD31+ naı¨ve CD4+ T-cells
[32,46], we investigated whether the relative fluorescence intensity
of CD31 on CD31+CD4+ naı¨ve T-cells was associated with
differing levels of TREC content. PBMC from five seronegative
participants were sorted into three subsets based on the relative
number of CD31 molecules on the surface of the cells:
CD31+brightCD4+, CD31+dimCD4+, and total CD31+CD4+
(Figure 3A). As shown in Figure 3B, the level of CD31 expression
was, in fact, strongly associated with TREC number in
CD31+CD4+ naive T-cells. The CD31+brightCD4+ naı¨ve T-cells
showed an average of 80% more TREC than were found within
total CD31+CD4+ naı¨ve T-cells, while the CD31+dimCD4+ naı¨ve
T-cell subset showed an average of 60% fewer TREC
(p = 0.0088). These data suggest that CD31+brightCD4+ naive T-
cells, as compared to CD31+dimCD4+ naı¨ve T-cells, are more
highly enriched in RTE that have not undergone proliferation.
Thus, relative fluorescence intensity can be used as an indirect
measure of proliferative history within RTE in situations where
cell numbers are limiting.
Successful ART treatment does not fully reconstitute the
CD31-CD4+ naı¨ve T-cell subset
Since we determined that HIV-1 infection has detrimental
effects on the absolute numbers of both naı¨ve CD4+ T-cell
subsets, we evaluated whether ART was able to restore these
subsets to age-appropriate levels. Using the CD31 marker as an
indicator of emigration of naı¨ve cells from the thymus, we
performed a longitudinal study on cryopreserved PBMC obtained
from MACS participants before, and after, initiation of ART.
One year post-ART, the absolute number of CD31+brightCD4+
naı¨ve T-cells significantly increased from an average of 60 cells/
mm3 to an average of 180 cells/mm3 (Figure 4, p = 0.0013). In
fact, 2 years post-ART there was no significant difference in cell
number between SP men and their SN age-matched controls
(p = 0.4904).
Since CD31+brightCD4+ naı¨ve T-cells appear to be enriched for
non-proliferated RTE (Figure 3B), the data in Figure 4 are
consistent with previous reports of measurable thymic emigration
after only one year of ART [43,47] and continuing after that
time. Interestingly, although there was no significant difference
between the CD31+CD4+ naı¨ve T-cell subset and SN controls
after 2 years of ART (p = 0.2670), the absolute number of
CD31-CD4+ naı¨ve T-cells at the same time point showed no
significant increase (Figure 5). The ultimate outcome, there-
fore, is a significant difference in CD31-CD4+ T-cell numbers
between SP and SN age-matched controls two years post-ART
(p = 0.0022).
Discussion
Our results demonstrate that the negative effects of HIV-1
infection and aging on naı¨ve CD4+ T-cells are predominantly
additive. However, HIV-1 infection also exerts a distinct negative
effect on CD31-CD4+ T-cell number that is not seen with aging.
Together, these results suggest a role for impaired helper T-cell
responses, particularly to neoantigens, in the more rapid
progression to AIDS observed in individuals 50 years of age or
older.
Older SN individuals demonstrate diminished absolute numbers
of CD31+CD4+ naı¨ve T-cells and shortened telomeres within
those subsets [27]. Both of these deficits undoubtedly contribute to
the well-documented reduced responses to vaccines and other
neoantigens well documented in older adults [29–31]. Indeed,
initial HIV-1 infection of older individuals is likely to be met with a
diminished CD4+ T-cell response, which, in turn, would affect
both B- and T-cell responses to HIV-1, allowing the virus to
spread quickly. Moreover, our results suggest that once infection is
established, the naı¨ve CD4+ T-cell compartment is further
impaired by an accelerated loss of CD31+CD4+ naı¨ve T-cells,
and a loss of CD31- naı¨ve T-cells that is not normally associated
with SN adults in their fifties [27]. Compounding this cell loss is
the additive effect of aging and HIV-1 infection on telomere
shortening within both subsets of naı¨ve CD4+ T-cells (Figure 2).
Since telomere length is associated with proliferative capacity,
those naı¨ve CD4+ T-cells still present after the initial HIV-1
infection would be unlikely to generate, or support, robust CD8+
T- and B-cell responses to HIV-1 or opportunistic infections. Not
only would HIV-1 be allowed to replicate more rapidly in older
adults, but there would also be less CD4+ T-cell reserves, due to
the reduced numbers of CD4+ T-cells and their progeny. These
effects would undoubtedly contribute to the more rapid progres-
sion to AIDS.
The underlying mechanisms for the accelerated loss of the naı¨ve
CD4+ T-cells during HIV-1 disease most likely include increased
recruitment into the effector/memory pool as well as direct
infection with HIV-1 and eventual cell death. The latter is
supported by previous reports showing that naı¨ve CD4+ T-cells
can be infected by HIV-1 [48,49]. Our own unpublished
observation that the CD31- naı¨ve subset harbors HIV-1 in vivo
in ART-naı¨ve individuals (data not shown) may also partially
explain why this subset declines in HIV-1-infected, but not age
matched SN, individuals.
Figure 2. Telomeres are significantly shortened in naı¨ve CD4+
T-cells within 1-3 years of HIV-1 infection. PBMC from each
individual in the cross-sectional study were sorted into CD31+CD4+and
CD31-CD4+ T-cell subsets. The sorted cells were then subjected to
telomere length Real-Time PCR. Telomere length values are expressed
as a percentage of telomere lengths within a human T-cell leukemia cell
line, 1301 cells. Each symbol represents a sample from a single
individual within the indicated serostatus and age group. The asterisks
signify the following values, * p#0.05, ** p#0.01, *** p,0.005.
doi:10.1371/journal.pone.0016459.g002
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Loss of the CD31-CD4+ naı¨ve T-cells subset, and failure of this
subset to reconstitute, is likely to have long-term deleterious effects
on the immune response to neoantigens in individuals treated with
ART. We previously demonstrated that homeostasis of the naı¨ve
CD4+ T-cell subset in adults is largely maintained by proliferation
of CD31-CD4+ naı¨ve T-cells and not by recent thymic emigrants
(CD31+CD4+ naı¨ve T-cells) [27]. Furthermore, the presence of
clonal expansions of naı¨ve CD31-CD4+ T-cells in HIV-1-infected
individuals, similar to those in the effector/memory CD4+ T-cell
pool, suggest that it is the CD31-CD4+ T-cells which are recruited
into the effector/memory pool in response to antigen (Kilpatrick,
et al. unpublished results). Failure of this subset to fully reconstitute
in the older SP group within 2 years after ART initiation (Figure 5)
suggests that, despite reconstitution of the CD31+ naı¨ve CD4+ T-
cell compartment shown by us and others [50], fewer naı¨ve CD4+
T-cells are available for recruitment into the effector/memory
pool, as compared to uninfected peers. The lack of reconstitution
could be due to a true ‘‘block’’ in differentiation from
CD31+CD4+ to CD31-CD4+, or by CD31-CD4+ T-cells being
rapidly recruited into the effector/memory pool to fill the
‘‘immunologic space’’. These two mechanisms would have very
different implications for the health of ART-treated individuals
and could suggest very different therapeutic strategies for
enhancing overall CD4+ T-cell reconstitution.
To our knowledge, this is the first study demonstrating
shortened telomere lengths in naı¨ve CD4+ T-cells sorted from
HIV-1-infected participants and subdivided by the surface
markers CD31 and CD27. While these data accord with the
majority of studies examining telomere length in total, or
effector/memory, CD4+ T-cell populations during HIV-1
infection [51–54], they do conflict with the findings of Miedema
and colleagues [55]. Using CD45RA and CD45RO to sort naı¨ve
and effector/memory cells, Wolthers et al. [55] failed to find
evidence of telomere shortening in either CD4+ T-cell subset
during HIV-1 infection. The difference between the Wolthers
et al. results and our own study may be due, at least in part, to a
difference in flow cytometry gating strategies. For example,
expression of CD45RA is not a stringent phenotype for naı¨ve
CD4+ T-cells; other cell types, such as terminally differentiated
cells would be included in this population. In addition, in contrast
to the Wolthers, et al. study, our own HIV-1 infected cohort was
age-matched to the SN controls to avoid the confounding effects
of aging on the telomere lengths within our HIV-1 infected
individuals.
Our observation of telomere shortening in even the least
differentiated naı¨ve CD4+ T-cells (i.e.,the CD31+CD4+ T-cell
subset) in response to both aging and HIV-1 infection (Figure 2) is
intriguing and implies possible telomere shortening in an earlier
progenitor cell. In support of this hypothesis, both HIV-1 infection
and aging have been linked to decreased telomerase activity within
hematopoietic progenitors [56–58]. Alternatively, it is possible that
extensive cellular proliferation, oxidative stress, or a deficit in
Figure 4. Seropositive individuals two years post-ART have significantly greater numbers of CD31+bright cells. Cryopreserved PBMC
from ten HIV-1 seropositive MACS participants collected at the indicated times pre- and post-ART were analyzed by flow cytometry for expression of
CD4, CD45RA, and CD31. Absolute numbers of CD31+brightCD4+ naı¨ve T-cells were determined for each participant at the indicated time points. The
data is shown in a box plot format where the top and bottom of the box represent the 25th and 75th percentile and middle band represents the 50th
percentile. The asterisks signify the following value, *** p,0.005.
doi:10.1371/journal.pone.0016459.g004
Figure 3. TREC content correlates with levels of CD31 expression on CD31+CD4+ naive T-cells. Fresh PBMC from five HIV-1 seronegative
individuals, ranging from 25-56 years of age, were sorted into total CD31+CD4+, CD31+brightCD4+ and CD31+dimCD4+ naı¨ve T-cell subsets. A.) Pre-sort
gates for determining the CD31+brightCD4+, CD31+dimCD4+, and CD31-CD4+ naı¨ve T-cell subsets are shown. The bottom three plots depict
representative post-sort analysis of the subsets. B.) Genomic DNA was extracted from each subset and subjected to quantitative Real-Time PCR to
quantify TREC content. The data is expressed as a percentage of TREC number in the indicated subset shown relative to TREC number in total
CD31+CD4+ naı¨ve T-cells. The asterisks signify the following value, ** p = 0.009.
doi:10.1371/journal.pone.0016459.g003
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telomerase directly contributes to telomere shortening within the
peripheral CD4+ naı¨ve T-cells. Our data do not support a major
role for extensive proliferation of the naı¨ve T-cells alone in the
telomere shortening. Based on the correlation between TREC
levels and CD31 expression (Figure 3B), we performed a cross-
sectional analysis of CD31 expression levels on naı¨ve CD31+
CD4+ T-cells from older vs. younger SN and HIV-1 infected age
matched adults, but did not find a diminution of the CD31 relative
fluorescence intensity that would be consistent with extensive
cellular turnover during aging or HIV-1 infection (data not
shown). In addition, in a previous cross-sectional study of the naı¨ve
CD4+ T-cell compartment during aging, we observed a significant
decline in TREC in naı¨ve CD31+ T cells over a 1-2 decade period
[27]. However, the T-cell expansion was subtle and unlikely to
completely account for the significant telomere shortening
associated with aging, suggesting that additional factors, possibly
oxidative stress, may be involved. Indeed, oxidative stress is
associated with chronic inflammation, which is well documented
in both HIV-1 infection [59] and aging [60–63] and is known to
accelerate telomere shortening in both the presence and absence
of proliferation [64,65].
Our results lead us to hypothesize that the additive effects of
HIV-1 and aging on the CD31+CD4+ naı¨ve T-cell subset, and the
HIV-1 associated loss of the CD31- naı¨ve CD4+ T-cells, contribute
to accelerated HIV-1 disease progression in HIV-1-infected adults
over the age of 50 [66,67], and to the decreased response to anti-
retroviral therapy in older HIV-1-infected adults [68,69].
Moreover, there is accumulating evidence that ART-treated
HIV-1-infected individuals clinically present with malignancies
and infectious diseases more consistent with older SN adults [3–
5,70,71]. Further elucidation of the mechanisms contributing to
naı¨ve CD4+ T-cell loss, telomere shortening, and delayed or
arrested reconstitution of the CD31- naı¨ve CD4+ T-cell subset may
lead to the identification of novel therapeutic targets to enhance
the immune response against HIV-1 and other pathogens, as well
as strategies to retard the formation of neoplasms in ART-treated
individuals.
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